Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01352520CT.gov SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | — | Active Not Recruiting | — | — | — |
NCT01396070CT.gov Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Panobinostat | Peter MacCallum Cancer Centre, Australia | P2 | B |
| Vorinostat | Stanford University | P1/2 | CCC |
| Tretinoin | Peter MacCallum Cancer Centre, Australia | P1 | CC |
| Romidepsin | Weiyun Ai | P1 | CC |
| Nivestim | Peter MacCallum Cancer Centre, Australia | P1 | CC |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | University of Zurich | P1 | CC |
| Adriamycin | Weiyun Ai | P1 | CC |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
+4 more in the Primary Cutaneous Lymphoma cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Primary Cutaneous Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-primary-cutaneous-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →